Seeking Alpha

Repros addresses ZA-302 questions, shares soar

  • In what may be an attempt to address some of the concerns raised about ZA-302 topline data, Repros Therapeutics (RPRX +6.7%) provides some additional confirmatory information regarding Androxal efficacy.
  • Notable: The phrase "statistically significant" is present in Wednesday's PR but was not included in Monday evening's release.
  • See also: Merrill raises price target on RPRX
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs